Association of Enolase-1 with Prognosis and Immune Infiltration in Breast Cancer by Clinical Stage

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: past, present and future. Semin Cancer Biol. 2018;52(Pt 1):56–73. doi:10.1016/j.semcancer.2017.08.010
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717. doi:10.1016/S0140-6736(05)66544-0
   PubMed Web of Science ®Google Scholar
• Byar DP, Sears ME, McGuire WL. Relationship between estrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancer. Eur J Cancer. 1979;15(3):299–310. doi:10.1016/0014-2964(79)90041-0
   Web of Science ®Google Scholar
• Patani N, Martin LA. Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer. Mol Cell Endocrinol. 2014;382(1):683–694. doi:10.1016/j.mce.2013.09.038
   Web of Science ®Google Scholar
• Diaz-Ramos A, Roig-Borrellas A, Garcia-Melero A, Lopez-Alemany R. alpha-Enolase, a multifunctional protein: its role on pathophysiological situations. J Biomed Biotechnol. 2012;2012:156795. doi:10.1155/2012/156795
   PubMedGoogle Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033. doi:10.1126/science.1160809
   PubMed Web of Science ®Google Scholar
• Niccolai E, Cappello P, Taddei A, et al. Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic factor for pancreatic adenocarcinoma. Int J Oncol. 2016;49(1):393–401. doi:10.3892/ijo.2016.3524
   Web of Science ®Google Scholar
• Mandili G, Curcio C, Bulfamante S, et al. In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination. J Immunother Cancer. 2020;8(2):e001071. doi:10.1136/jitc-2020-001071
   Web of Science ®Google Scholar
• Zhang C, Zhang K, Gu J, Ge D. ENO1 promotes antitumor immunity by destabilizing PD-L1 in NSCLC. Cell Mol Immunol. 2021;18(8):2045–2047. doi:10.1038/s41423-021-00710-y
   Web of Science ®Google Scholar
• Liu S, Sun X, Li K, et al. Generation of the tumor-suppressive secretome from tumor cells. Theranostics. 2021;11(17):8517–8534. doi:10.7150/thno.61006
   Web of Science ®Google Scholar
• Li K, Sun X, Zha R, et al. Counterintuitive production of tumor-suppressive secretomes from Oct4- and c-Myc-overexpressing tumor cells and MSCs. Theranostics. 2022;12(7):3084–3103. doi:10.7150/thno.70549
   Web of Science ®Google Scholar
• Mojtahedi Z, Safaei A, Yousefi Z, Ghaderi A. Immunoproteomics of HER2-positive and HER2-negative breast cancer patients with positive lymph nodes. OMICS. 2011;15(6):409–418. doi:10.1089/omi.2010.0131
   Web of Science ®Google Scholar
• Cappello P, Principe M, Bulfamante S, Novelli F. Alpha-Enolase (ENO1), a potential target in novel immunotherapies. Front Biosci. 2017;22:944–959. doi:10.2741/4526
   PubMed Web of Science ®Google Scholar
• Cappello P, Rolla S, Chiarle R, et al. Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer. Gastroenterology. 2013;144(5):1098–1106. doi:10.1053/j.gastro.2013.01.020
   PubMed Web of Science ®Google Scholar
• Qiao H, Wang Y, Zhu B, et al. Enolase1 overexpression regulates the growth of gastric cancer cells and predicts poor survival. J Cell Biochem. 2019;120(11):18714–18723. doi:10.1002/jcb.29179
   Web of Science ®Google Scholar
• Cheng Z, Shao X, Xu M, Zhou C, Wang J. ENO1 acts as a prognostic biomarker candidate and promotes tumor growth and migration ability through the regulation of Rab1A in colorectal cancer. Cancer Manag Res. 2019;11:9969–9978. doi:10.2147/CMAR.S226429
   PubMed Web of Science ®Google Scholar
• Zhu W, Li H, Yu Y, et al. Enolase-1 serves as a biomarker of diagnosis and prognosis in hepatocellular carcinoma patients. Cancer Manag Res. 2018;10:5735–5745. doi:10.2147/CMAR.S182183
   PubMed Web of Science ®Google Scholar
• Lomnytska MI, Becker S, Gemoll T, et al. Impact of genomic stability on protein expression in endometrioid endometrial cancer. Br J Cancer. 2012;106(7):1297–1305. doi:10.1038/bjc.2012.67
   PubMed Web of Science ®Google Scholar
• Chang YS, Wu W, Walsh G, Hong WK, Mao L. Enolase-alpha is frequently down-regulated in non-small cell lung cancer and predicts aggressive biological behavior. Clin Cancer Res. 2003;9(10 Pt 1):3641–3644.
   Web of Science ®Google Scholar
• White-Al Habeeb NM, Di Meo A, Scorilas A, et al. Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma. Clin Exp Metastasis. 2015;32(6):531–541. doi:10.1007/s10585-015-9725-2
   Web of Science ®Google Scholar
• Cancemi P, Buttacavoli M, Roz E, Feo S. Expression of alpha-enolase (ENO1), myc promoter-binding protein-1 (MBP-1) and matrix metalloproteinases (MMP-2 and MMP-9) reflect the nature and aggressiveness of breast tumors. Int J Mol Sci. 2019;20:16. doi:10.3390/ijms20163952
   Web of Science ®Google Scholar
• Xu W, Yang W, Wu C, Ma X, Li H, Zheng J. Enolase 1 correlated with cancer progression and immune-infiltrating in multiple cancer types: a pan-cancer analysis. Front Oncol. 2020;10:593706. doi:10.3389/fonc.2020.593706
   Web of Science ®Google Scholar
• Zhou M, Chen QX, Yang YZ, et al. Prognostic value of glutaminase 1 in breast cancer depends on H3K27me3 expression and menopausal status. Virchows Archiv. 2022;480(2):259–267. doi:10.1007/s00428-021-03210-6
   Web of Science ®Google Scholar
• Chen QX, Yang YZ, Liang ZZ, et al. Time-varying effects of FOXA1 on breast cancer prognosis. Breast Cancer Res Treat. 2021;187(3):867–875. doi:10.1007/s10549-021-06125-7
   Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337
   PubMed Web of Science ®Google Scholar
• Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG. Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration. J Natl Cancer Inst. 2018;110(8):803–811. doi:10.1093/jnci/djy088
   PubMedGoogle Scholar
• Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol. 2005;6(3):280–286. doi:10.1038/ni1165
   PubMed Web of Science ®Google Scholar
• Adema GJ. Dendritic cells from bench to bedside and back. Immunol Lett. 2009;122(2):128–130. doi:10.1016/j.imlet.2008.11.017
   PubMed Web of Science ®Google Scholar
• Gunassekaran GR, Poongkavithai Vadevoo SM, Baek MC, Lee B. M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials. 2021;278:121137. doi:10.1016/j.biomaterials.2021.121137
   PubMed Web of Science ®Google Scholar
• Laria A, Lurati A, Marrazza M, Mazzocchi D, Re KA, Scarpellini M. The macrophages in rheumatic diseases. J Inflamm Res. 2016;9:1–11. doi:10.2147/JIR.S82320
   PubMed Web of Science ®Google Scholar
• Hollern DP, Xu N, Thennavan A, et al. B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer. Cell. 2019;179(5):1191–1206 e1121. doi:10.1016/j.cell.2019.10.028
   PubMed Web of Science ®Google Scholar
• Ali HR, Provenzano E, Dawson SJ, et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014;25(8):1536–1543. doi:10.1093/annonc/mdu191
   PubMed Web of Science ®Google Scholar
• Schreiber S, Hammers CM, Kaasch AJ, Schraven B, Dudeck A, Kahlfuss S. Metabolic interdependency of Th2 cell-mediated type 2 immunity and the tumor microenvironment. Front Immunol. 2021;12:632581. doi:10.3389/fimmu.2021.632581
   Web of Science ®Google Scholar
• Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19(3):200–218. doi:10.1038/s41573-019-0052-1
   PubMed Web of Science ®Google Scholar
• Cappello P, Tomaino B, Chiarle R, et al. An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. Int J Cancer. 2009;125(3):639–648. doi:10.1002/ijc.24355
   PubMed Web of Science ®Google Scholar
• Cook K, Daniels I, Symonds P, et al. Citrullinated alpha-enolase is an effective target for anti-cancer immunity. Oncoimmunology. 2018;7(2):e1390642. doi:10.1080/2162402X.2017.1390642
   Web of Science ®Google Scholar
• Chong C, Coukos G, Bassani-Sternberg M. Identification of tumor antigens with immunopeptidomics. Nat Biotechnol. 2022;40(2):175–188. doi:10.1038/s41587-021-01038-8
   PubMed Web of Science ®Google Scholar
• Yoshihama S, Vijayan S, Sidiq T, Kobayashi KS. NLRC5/CITA: a key player in cancer immune surveillance. Trends Cancer. 2017;3(1):28–38. doi:10.1016/j.trecan.2016.12.003
   PubMed Web of Science ®Google Scholar
• Gil Del Alcazar CR, Huh SJ, Ekram MB, et al. Immune escape in breast cancer during in situ to invasive carcinoma transition. Cancer Discov. 2017;7(10):1098–1115. doi:10.1158/2159-8290.CD-17-0222
   PubMed Web of Science ®Google Scholar
• Liu Y, Komohara Y, Domenick N, et al. Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunol Immunother. 2012;61(6):789–801. doi:10.1007/s00262-011-1137-9
   PubMed Web of Science ®Google Scholar
• Gil Del Alcazar CR, Aleckovic M, Polyak K. Immune escape during breast tumor progression. Cancer Immunol Res. 2020;8(4):422–427. doi:10.1158/2326-6066.CIR-19-0786
   Web of Science ®Google Scholar
• Khan M, Arooj S, Wang H. Soluble B7-CD28 family inhibitory immune checkpoint proteins and anti-cancer immunotherapy. Front Immunol. 2021;12:651634. doi:10.3389/fimmu.2021.651634
   Web of Science ®Google Scholar
• Lentz RW, Colton MD, Mitra SS, Messersmith WA. Innate immune checkpoint inhibitors: the next breakthrough in medical oncology? Mol Cancer Ther. 2021;20(6):961–974. doi:10.1158/1535-7163.MCT-21-0041
   PubMed Web of Science ®Google Scholar
• Criscitiello C, Esposito A, Gelao L, et al. Immune approaches to the treatment of breast cancer, around the corner? Breast Cancer Res. 2014;16(1):204. doi:10.1186/bcr3620
   Web of Science ®Google Scholar
• Kulkarni YM, Suarez V, Klinke DJ. Inferring predominant pathways in cellular models of breast cancer using limited sample proteomic profiling. BMC Cancer. 2010;10:291. doi:10.1186/1471-2407-10-291
   Web of Science ®Google Scholar
• Zhang D, Tai LK, Wong LL, Chiu LL, Sethi SK, Koay ES. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics. 2005;4(11):1686–1696. doi:10.1074/mcp.M400221-MCP200
   PubMed Web of Science ®Google Scholar
• Didiasova M, Zakrzewicz D, Magdolen V, et al. STIM1/ORAI1-mediated Ca2+ influx regulates enolase-1 exteriorization. J Biol Chem. 2015;290(19):11983–11999. doi:10.1074/jbc.M114.598425
   Web of Science ®Google Scholar
• Silvestrini R, Daidone MG, Luisi A, et al. Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol. 1995;13(3):697–704. doi:10.1200/JCO.1995.13.3.697
   Web of Science ®Google Scholar
• Bundred NJ. Prognostic and predictive factors in breast cancer. Cancer Treat Rev. 2001;27(3):137–142. doi:10.1053/ctrv.2000.0207
   PubMed Web of Science ®Google Scholar
• Li S, Wu J, Huang O, et al. HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab. Breast. 2020;54:235–241. doi:10.1016/j.breast.2020.10.002
   Web of Science ®Google Scholar
• Allison KH. Prognostic and predictive parameters in breast pathology: a pathologist’s primer. Mod Pathol. 2021;34(Suppl 1):94–106. doi:10.1038/s41379-020-00704-7
   Google Scholar
• Fei F, Zhang K, Siegal GP, Wei S. A simplified breast cancer prognostic score: comparison with the AJCC clinical prognostic staging system. Mod Pathol. 2021;34(12):2141–2147. doi:10.1038/s41379-021-00890-y
   Web of Science ®Google Scholar